

SOOLANTRA[®]

(ivermectin CREAM, 1%)

ABOUT SOOLANTRA CREAM (/HCP/ABOUT-SOOLANTRA-CREAM).

EFFICACY ▼

PATIENT BURDEN (/HCP/PATIENT-BURDEN).

TOLERABILITY (/HCP/TOLERABILITY).

PATIENT SAVINGS (/HCP/PATIENT-SAVINGS).

SIGN UP (/HCP/SIGN-UP).

NOT AN ACTUAL PATIENT

Soolantra Cream combats inflammatory lesions of rosacea with a formulation designed for tolerability, utilizing Cetaphil[®] Moisturizing Cream as the basis for the vehicle.¹

OTHER TREATMENT OPTIONS ▼

FOR CONSUMERS (/).

PRESCRIBING INFORMATION

([HTTPS://WWW.GALDERMA.COM/US/SITES/G/FILES/JCDFHC341/FILES/2019-01/SOOLANTRA_CREAM_PI.PDF](https://www.galderma.com/us/sites/g/files/jcdfhc341/files/2019-01/soolantra_cream_pi.pdf)).

Proposed dual MOA of ivermectin²-5,a



ANTI-INFLAMMATORY

- Decreases cellular and humoral immune responses
- Parent compound avermectin has been shown to significantly regulate TNF- α , IL-1 β , and IL-10 in lipopolysaccharide-induced inflammation in in vitro studies




ANTIPARASITIC

- Vermicide
- Demodex
 - Published clinical case series

^aThe mechanism of action (MOA) of Soolantra[®] (ivermectin) Cream, 1% in treating rosacea lesions is unknown.



Interview with Dr. Linda Stein Gold, Soolantra Cream Clinical Investigator



Soolantra Cream application instructions

Instruct patients to:

Apply Soolantra Cream to the affected areas of the face once a day. Use a pea-sized amount of Soolantra Cream for each area of the face (forehead, chin, nose, each cheek) that is affected. Spread as a thin layer across the affected areas of the face, avoiding the eyes and lips.

- Hands should be washed after applying Soolantra Cream
- Cosmetics may be applied after Soolantra Cream has dried
- Soolantra Cream is not for oral, ophthalmic, or intravaginal use



IMPORTANT SAFETY INFORMATION

Indication: SOOLANTRA® (ivermectin) Cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use. **Adverse Events:** In clinical trials with SOOLANTRA® Cream, the most common adverse reactions (incidence $\leq 1\%$) included skin burning sensation and skin irritation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [WWW.FDA.GOV/MEDWATCH](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) (<https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program>) or call 1-800-FDA-1088.

***Rosacea: Beyond the visible report - Methods:** Self-administered online survey covered 554 physicians and 710 patients from France, Germany, Italy, UK, Canada and the U.S. Participants were recruited using the Kantar online panel. In order to maximize the sample size no quota was set up. Therefore, the sample is not representative of the rosacea population of each country. **Inclusion criteria for patients:** Adults from 18 to 70 years of age, suffering with rosacea as diagnosed by a physician (Declarative), having taken a prescribed treatment in the past 12 months, and visited a physician at least twice in the past 12 months.

**The BURDEN survey is developed by Kantar Health as a self-administered online survey and supported by Galderma International. Participants were recruited using the Kantar online panel. In order to maximize the sample size no quota was set up. Therefore, the sample is not representative of the rosacea population in each country; consequently, the results of this study could be affected by selection bias and cannot be inferred to the whole rosacea population.

†www.rosacea.org

References: **1.** Data on file. Galderma Laboratories, L.P. **2.** Stankiewicz M, Cabaj W, Jonas WE, Moore LG, Millar K, Ng Chie W. Influence of ivermectin on cellular and humoral immune responses of lambs. *Vet Immunol and Immunopathol.* 1995;44:347-358. **3.** Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? *J Antimicrob Chemother.* 1998;41(suppl B):37-46. **4.** Ci X, Li H, Yu Q, et al. Ivermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. *Fundam Clin Pharmacol.* 2009;23:449-455. **5.** S. Del Rosso JQ, Gallo RL, Kircik L, Thiboutot D, Baldwin HE, Cohen D. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. *J Drugs Dermatol.* 2012;11(6):694-700.

Privacy Policy (<https://www.galderma.com/us/your-data>)

Legal Notice Policy (<https://www.galderma.com/us/legal>)

Contact Us (<https://www.galderma.com/us/contact-us>)

About Galderma (<https://www.galderma.com/us/>)

Site Map (</consumer/sitemap>)

California - Do Not Sell My Personal Information

(<https://www.emailmeform.com/builder/form/PyYfUp0ltf0bXBb>)

See Important Safety Information



© 2020 Galderma Laboratories, L.P. United States, All Rights Reserved. All trademarks are the property of their respective owners.